14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η’s clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to...
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From...
In a study of over 800 rheumatoid arthritis (RA) patients, presented this week at the Canadian Rheumatology (CRA) Association Meeting, it was shown that a positive 14-3-3η blood test amplified the risk of rapid joint damage progression when added to current measures....
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
